Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial CarcinomaBusiness Wire • 02/03/23
Merck Lands In Hot Water After 2023 Profit Guidance Widely Misses ForecastsInvestors Business Daily • 02/02/23
Merck stock falls after quarterly earnings top expectations but profit outlook disappointsMarket Watch • 02/02/23